Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 3:4:100131.
doi: 10.1016/j.crpvbd.2023.100131. eCollection 2023.

Efficacy of Felpreva®, a new spot-on formulation containing tigolaner, emodepside and praziquantel, applied as a single application to cats artificially infested with ear mites (Otodectes cynotis)

Affiliations

Efficacy of Felpreva®, a new spot-on formulation containing tigolaner, emodepside and praziquantel, applied as a single application to cats artificially infested with ear mites (Otodectes cynotis)

Katrin Blazejak et al. Curr Res Parasitol Vector Borne Dis. .

Abstract

The efficacy of Felpreva® (Vetoquinol), a new spot-on application containing the novel acaricide and insecticide tigolaner in combination with emodepside and praziquantel, was evaluated in cats artificially infested with ear mites (Otodectes cynotis). A total of three pivotal dose confirmation studies were conducted, two of them designed as non-interference studies. Cats were artificially infested with O. cynotis mites and randomly allocated into groups of 8 cats based on pre-treatment mite counts. Cats were treated once on Day 0, either with Felpreva® (14.5 ​mg/kg tigolaner, 3 ​mg/kg emodepside and 12 ​mg/kg praziquantel) or with placebo. Studies with a non-interference design included two additional groups of cats, treated with Profender® spot-on solution (Vetoquinol) (3 ​mg/kg emodepside and 12 ​mg/kg praziquantel) and tigolaner as a mono product (14.5 ​mg/kg tigolaner). Efficacy was evaluated on Day 28/Day 30 based on total live mite counts after ear flushing. Efficacy was claimed when: (i) at least six control cats per group were adequately infested with mites; (ii) calculated efficacy was ≥ 90% based on geometric mean mite counts; and (iii) the difference in mite counts between Felpreva®-treated cats and control cats was statistically significant (P ​≤ ​0.05). In two of the three studies, Felpreva®-treated cats were mite-free (100% efficacy) on Day 28/Day 30 and almost full efficacy (99.6%) was seen in the third study. The difference in mite counts between Felpreva®-treated cats and control cats was significant (P ​< ​0.0001) in all three studies. All control cats were adequately infested in all three studies. The efficacy of Felpreva® against ear mite (Otodectes cynotis) infection in cats was confirmed.

Keywords: Cat; Ear mite; Felpreva®; Otoacariosis; Otodectes cynotis; Tigolaner.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hannah Ringeisen and Gabriele Petry were employees of Bayer Animal Health GmbH, an Elanco Animal Health Company at the time while the studies reported here were conducted. Katrin Blazejak and Norbert Mencke are employees of Vetoquinol S.A., Paris, France. Tanya N. Knoppe is owner of Vet Advice, Hamburg, Germany. Alta Viljoen is an employee of Clinvet International (Pty) Ltd, Blomfontein, South Africa. Reinier Zwiegers and Roland Klopper are employees of ClinData Blomfontein, South Africa. Jennifer Spruill, Ronald K. Tessman and Terry Settje are employees of Elanco Animal Health, Greenfield, USA. David R. Young was owner of Young Veterinary Research Services, Turlock, CA, USA. Douglas Shane is employee of Young Veterinary Research Services, Turlock, CA, USA.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
Changes of post-treatment Otodectes cynotis visible live mite count scores in relation to pre-treatment assessed by otoscopic examination (effect of treatment based on worst case score between both ears on Day 14 and Day 28 versus pre-treatment (Day -2/Day -3) in comparison to placebo, Cochran-Mantel-Haenszel test, level of significance ​= ​0.05).
Fig. 2
Fig. 2
Changes of post-treatment debris/cerumen scores in relation to pre-treatment assessed by otoscopic examination (effect of treatment based on worst case score between both ears on Day 14 and Day 28 versus pre-treatment (Day -2/Day -3) in comparison to placebo, Cochran-Mantel-Haenszel test, level of significance ​= ​0.05).

Similar articles

Cited by

References

    1. Becskei C., Reinemeyer C., King V.L., Lin D., Myers M.R., Vatta A.F. Efficacy of a new spot-on formulation of selamectin plus sarolaner in the treatment of Otodectes cynotis in cats. Vet. Parasitol. 2017;238(Suppl. 1):S27–S30. - PubMed
    1. Beugnet F., Bourdeau P., Chalvet-Monfray K., Cozma V., Farkas R., Guillot J., et al. Parasites of domestic owned cats in Europe: Co-infestations and risk factors. Parasites Vectors. 2014;7:291. - PMC - PubMed
    1. Bowman D.D., Hendrix C.M., Lindsay D.S., Barr S.C. 1st ed. Blackwell Science, Iowa State University Press; Iowa, USA: 2002. Feline Clinical Parasitology; pp. 389–394.
    1. Brame B., Cain C. Chronic otitis in cats: Clinical management of primary, predisposing and perpetuating factors. J. Feline Med. Surg. 2021;23:433–446. - PMC - PubMed
    1. CAPC, 2019. CAPC guidelines. Otodectic mange. Companion Animal Parasite Council. https://capcvet.org/guidelines/otodectic-mite/. (Accessed 8 November 2022).

LinkOut - more resources